MYRIAD GENETICS, INC. Financials Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.18 USD | +1.11% |
|
-1.73% | -5.02% |
| Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
| Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,026 | 1,487 | 2,204 | 1,176 | 1,697 | 1,645 | - | - |
| Enterprise Value (EV) 1 | 2,122 | 1,595 | 1,864 | 1,061 | 1,595 | 1,623 | 1,656 | 1,652 |
| P/E ratio | 454 x | -6.42 x | -78.9 x | -10.4 x | -6.02 x | -19.6 x | -29.3 x | -79 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.38 x | 2.67 x | 3.19 x | 1.73 x | 2.25 x | 1.99 x | 1.83 x | 1.72 x |
| EV / Revenue | 2.49 x | 2.86 x | 2.7 x | 1.56 x | 2.12 x | 1.96 x | 1.85 x | 1.73 x |
| EV / EBITDA | 9.73 x | - | 25.9 x | -50.5 x | -253 x | 71.1 x | 24.3 x | 15.8 x |
| EV / FCF | 28.3 x | -24.7 x | 11.5 x | -7 x | -9.16 x | 180 x | 69 x | 31.8 x |
| FCF Yield | 3.54% | -4.05% | 8.7% | -14.3% | -10.9% | 0.55% | 1.45% | 3.15% |
| Price to Book | 1.84 x | 1.69 x | 2.28 x | 1.33 x | 2.2 x | 2.58 x | 2.61 x | 2.46 x |
| Nbr of stocks (in thousands) | 74,389 | 75,210 | 79,855 | 81,034 | 88,669 | 90,478 | - | - |
| Reference price 2 | 27.23 | 19.78 | 27.60 | 14.51 | 19.14 | 18.18 | 18.18 | 18.18 |
| Announcement Date | 8/13/19 | 2/23/21 | 2/24/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 851.1 | 557 | 690.6 | 678.4 | 753.2 | 827.9 | 896.6 | 957.1 |
| EBITDA 1 | 218.2 | - | 71.9 | -21 | -6.3 | 22.82 | 68.19 | 104.7 |
| EBIT 1 | 145.2 | -77.9 | 9.1 | -32.8 | -25.5 | 4.084 | 28.37 | 49.59 |
| Operating Margin | 17.06% | -13.99% | 1.32% | -4.83% | -3.39% | 0.49% | 3.16% | 5.18% |
| Earnings before Tax (EBT) 1 | - | - | -57.1 | -140.6 | -262.2 | -104.6 | -75.29 | -47 |
| Net income 1 | 4.6 | - | -27.2 | -112 | -263.3 | -91.08 | -64.5 | -34.59 |
| Net margin | 0.54% | - | -3.94% | -16.51% | -34.96% | -11% | -7.19% | -3.61% |
| EPS 2 | 0.0600 | -3.080 | -0.3500 | -1.390 | -3.180 | -0.9260 | -0.6200 | -0.2300 |
| Free Cash Flow 1 | 75.1 | -64.6 | 162.2 | -151.6 | -174.1 | 9 | 24 | 52 |
| FCF margin | 8.82% | -11.6% | 23.49% | -22.35% | -23.11% | 1.09% | 2.68% | 5.43% |
| FCF Conversion (EBITDA) | 34.42% | - | 225.59% | - | - | 39.44% | 35.2% | 49.65% |
| FCF Conversion (Net income) | 1,632.61% | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/19 | 2/23/21 | 2/24/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 167.3 | 160.8 | 164.9 | 179.3 | 156.4 | 177.8 | 181.2 | 183.5 | 191.9 | 196.6 | 193.3 | 204 | 211.7 | 218.7 | 209.8 |
| EBITDA 1 | 12.8 | 13.4 | 10.2 | 7.3 | -17.6 | -10.7 | -20.5 | -4.2 | 1.2 | 10.1 | -5.55 | 4.4 | 9.55 | 14.3 | - |
| EBIT 1 | -1.4 | 0.1 | -2.8 | 4.5 | -20.6 | -13.9 | -21.9 | -6.8 | -2.2 | 5.7 | -12.19 | 0.6367 | 5.796 | 9.99 | -1.669 |
| Operating Margin | -0.84% | 0.06% | -1.7% | 2.51% | -13.17% | -7.82% | -12.09% | -3.71% | -1.15% | 2.9% | -6.31% | 0.31% | 2.74% | 4.57% | -0.8% |
| Earnings before Tax (EBT) 1 | 39.8 | -43.5 | -26.4 | -17.9 | -44.2 | -52.1 | -52.6 | -116.1 | -61.2 | -32.3 | -34.2 | -22.88 | -18.58 | -13.22 | -22.39 |
| Net income 1 | 24.6 | -7.6 | -20.5 | -14.1 | -35.1 | -42.3 | -54.7 | -116.1 | -61.3 | -31.2 | -31.38 | -20.24 | -16.04 | -10.75 | -20.29 |
| Net margin | 14.7% | -4.73% | -12.43% | -7.86% | -22.44% | -23.79% | -30.19% | -63.27% | -31.94% | -15.87% | -16.24% | -9.92% | -7.58% | -4.91% | -9.67% |
| EPS 2 | 0.3000 | -0.1000 | -0.2600 | -0.1800 | -0.4300 | -0.5200 | -0.6700 | -1.420 | -0.7500 | -0.3600 | -0.3025 | -0.1975 | -0.1600 | -0.1050 | -0.2233 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/1/22 | 2/28/23 | 5/3/23 | 8/3/23 | 11/6/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 96.6 | 108 | - | - | - | - | 10.9 | 7.58 |
| Net Cash position 1 | - | - | 340 | 115 | 102 | 22 | - | - |
| Leverage (Debt/EBITDA) | 0.4427 x | - | - | - | - | - | 0.1601 x | 0.0724 x |
| Free Cash Flow 1 | 75.1 | -64.6 | 162 | -152 | -174 | 9 | 24 | 52 |
| ROE (net income / shareholders' equity) | 12.4% | -5.6% | 0.15% | -12.1% | -2.71% | 0.33% | 4.06% | 8.1% |
| ROA (Net income/ Total Assets) | 9.27% | -3.57% | 0.1% | -1.92% | -1.93% | -5.62% | -4.53% | -1.42% |
| Assets 1 | 49.62 | - | -26,667 | 5,830 | 13,662 | 1,620 | 1,425 | 2,442 |
| Book Value Per Share 2 | 14.80 | 11.70 | 12.10 | 10.90 | 8.710 | 7.040 | 6.970 | 7.400 |
| Cash Flow per Share 2 | 1.100 | - | 0.2300 | -1.320 | -1.340 | 0.3200 | 0.6500 | - |
| Capex 1 | 8.6 | 10.2 | 18 | 45.3 | 63.2 | 19 | 20 | 21.5 |
| Capex / Sales | 1.01% | 1.83% | 2.61% | 6.68% | 8.39% | 2.29% | 2.23% | 2.25% |
| Announcement Date | 8/13/19 | 2/23/21 | 2/24/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
18.18
USD
Average target price
24.08
USD
Spread / Average Target
+32.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.02% | 1.64B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- MYGN Stock
- Financials Myriad Genetics, Inc.
